Has Bryce Nelson received payments from drug or device companies?

Yes. Drug and device makers reported $115,109 in general payments to Bryce Nelson across 74 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Bryce Nelson did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Bryce Nelson come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Bryce Nelson

Pediatric Endocrinology · Richmond, VANPI 1740337690

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $89,238 of the $115,109 with a category attached, or 77.5%. Sanofi-aventis U.S. LLC accounts for 98.7% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2024 at $52,742 and has fallen 55.8% since, to $23,335 in 2025. Among pediatric endocrinology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$115,109in general payments, 2019–2025

Across 74 payments — averaging $1555.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi-aventis U.S. LLC$114K
Mannkind Corporation$1K
Insulet Corporation$186
Abbott$26
Tolmar Pharmaceuticals, Inc.$25
Roche Diabetes Care, Inc.$22

$382,089in research payments, 2019–2025

Across 1,292 payments — averaging $295.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Mannkind Corporation$163K
Novo Nordisk AS$108K
Boehringer Ingelheim$83K
Boehringer Ingelheim Pharma GmbH & Co.kg$20K
Astrazeneca UK Limited$5K
Boehringer Ingelheim France S.a.s.$3K

What the payments were for

Consulting fees$18,43516%
Speaking & faculty fees$89,23878%
Travel & lodging$5,0934%
Food & beverage$2,2952%
Education$480%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi-aventis U.S. LLC	65	$113,574
Mannkind Corporation	1	$1,275
Insulet Corporation	2	$186
Abbott	2	$26
Tolmar Pharmaceuticals, Inc.	2	$25
Roche Diabetes Care, Inc.	2	$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

TZIELD$86,958
AFREZZA$1,275
Omnipod$150

How this compares

$115,109 in reported general payments places this provider in the 95th percentile of 36 pediatric endocrinology providers in Virginia.

See all pediatric endocrinology providers in Virginia →

Other pediatric endocrinology in Richmond

Edmond WickhamRichmond$2K
Elna KochummenRichmond$1K
Anil RamaswamyRichmond$1K
Arti ShahRichmond$415
Ladan Davallow GhajarRichmond$241
Mareen ThomasRichmond$185
Ashlyn CoxRichmond$162
Jessica RadcliffeRichmond$134
Leslie FergusonRichmond$51
Craig RudlinRichmond$47

See the full list for Virginia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →